Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease - a simulation study

Current Alzheimer Research

Volumn 10, Issue 2, 2013, Pages 207-216

  Sköldunger, Anders ^a   Johnell, Kristina ^a   Winblad, Bengt ^a   Wimo, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Mortality

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEMOGRAPHY; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; SURVIVAL;

ALZHEIMER DISEASE; COGNITION DISORDERS; COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MARKOV CHAINS; MODELS, THEORETICAL; SWEDEN;

EID: 84874879020     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011310020011     Document Type: Article

References (36)

1. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimer's and Dementia 6(2): 98-103 (2010).
2. Drummond MF, Sculper MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2004.
3. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363(9427): 2105-15 (2004).
4. Iliffe S. The National Institute for Health and Clinical Excellence (NICE) and drug treatment for Alzheimer's disease. CNS Drugs 21(3): 177-84 (2007).
5. Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15(1): 44-54 (2003).
6. Rizzuto D, Bellocco R, Kivipelto M, Clerici F, Wimo A, Fratiglioni L. Dementia after Age 75: Survival in Different Severity Stages and Years of Life Lost. Curr Alzheimer Res 9(7): 795-800 (2012).
7. SBU. Dementia. A systematic review. Stockholm: Staten beredning för medicinsk utvärdering (SBU) (The Swedish Council on Technology Assessment in Health Care) 2008. Report No.: 172E/1-3.
8. Sonnenberg FA, Leventhal EA. Modeling disease progression with Markov models. In: Wimo A, Jonsson B, Karlsson G, Winblad B, editors. Health economics of dementia. London, UK: John Wiley and sons; 1998. p. 171-96.
9. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM IV). 4th ed. Washington: American Psychiatric Association; 1994.
10. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3): 189-98 (1975).
11. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256(3): 240-6 (2004).
12. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 16(2):129-40 (2004).
13. Demographic statistics [database on the Internet]. Statistics Sweden. 2005.
14. Wimo A, Johansson L, Jönsson L. Demenssjukdomarnas samhällskostnader och antalet dementa i Sverige 2005 (The societal costs of dementia and the number of demented in Sweden 2005) (in Swedish). Stockholm: Socialstyrelsen 2007. Report No.: 2007-123-32.
15. Fratiglioni L, Viitanen M, Backman L, Sandman PO, Winblad B. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 11 (1): 29-36 (1992).
16. Nordberg G, von Strauss E, Kåreholt I, Johansson L, Wimo A. The amount of informal and formal care among non-demented and demented elderly persons - results from a Swedish population based study. Int J Geriatr Psychiatry 20(9): 862-71 (2005).
17. Jonsson L, Winblad B, Fratiglioni L, Wimo A. Mortality in relation to disese severity in subjects with dementia (Abstract). ISPOR; September 8-10 2011; Mexico city2011.
18. Wimo A, Johansson L, Jönsson L. Har demenssjukdomarnas samhällskostnader förändrats mellan 2000 och 2005? Läkartidningen 106(18-19):1277-82 (2009).
19. Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials - a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winblad B, editors. The Health Economis of dementia. London: John Wiley & Sons; 1998. p. 465-99.
20. Wimo A, Prince M. World Alzheimer report 2010. The global economic impact of dementia. London 2010.
21. Ekman M, Berg J, Wimo A, Jonsson L, McBurney C. Health utilities in mild cognitive impairment and dementia: a population study in Sweden. Int J Geriatr Psychiatry 22(7): 649-55 (2007).
22. Marengoni A, von Strauss E, Rizzuto D, Winblad B, Fratiglioni L. The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med 265(2): 288-95 (2009).
23. Guehne U, Angermeyer MC, Riedel-Heller S. Is mortality increased in mildly cognitively impaired individuals? A systematic literature review. Dement Geriatr Cogn Disord 21(5-6): 403-10 (2006).
24. Lagergren M, Fratiglioni L, Hallberg IR, Berglund J, Elmstahl S, Hagberg B, et al. A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC). Aging Clin Exp Res 16(2): 158-68 (2004).
25. Nordberg G, Strauss E, Kåreholt I, Johansson L, Wimo A. The amount of informal and formal care among non-demented and demented elderly persons - results from a Swedish population-based study. Int J Geriatr Psychiatry 20(9): 862-71 (2005).
26. Läkemedelsförmånsverket T-o. TLV:s uppdrag angående omregleringen av apoteksmarknaden. 2010 20100413.
27. Riksbank.se. http://www.riksbank.se/templates/stat.aspx?id=16749. [Web page]: Sveriges Riksbank; [cited 2010 sep 15].
28. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 270-9 (2011).
29. Budd D, Burns LC, Guo Z, L'Italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation. Clinicoecon Outcomes Res 3: 189-95 (2011).
30. Getsios D, Migliaccio-Walle K, Caro JJ. NICE cost-effectiveness appraisal of cholinesterase inhibitors: was the right question posed? Were the best tools used? Pharmacoeconomics 25(12): 997-1006 (2007).
31. Getsios D, Blume S, Ishak KJ, Maclaine G, Hernandez L. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom. Alzheimer's and Dementia(0).
32. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 9(7): 702-16 (2010).
33. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 263-9 (2011).
34. de Meijer C, Brouwer W, Koopmanschap M, van den Berg B, van Exel J. The value of informal care--a further investigation of the feasibility of contingent valuation in informal caregivers. Health Econ 19(7): 755-71 (2010).
35. Demographic statistics [database on the Internet]. 2010.
36. Svedem. Swedish Dementia Registry (Data on file). 2011.